TriangleMRX-2843 + Osimertinib (NCT04762199)
MRX-2843 + Osimertinib trial for Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NCT04762199). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced non-small cell lung cancer with an EGFR mutation.
The idea: combine osimertinib, a standard pill for EGFR mutant lung cancer, with MRX-2843, a pill that blocks two enzymes, MerTK and FLT3. Blocking enzymes the cancer needs may stop tumor cells from growing.
The study looks for the best dose of MRX-2843 and its side effects.
This phase 1 study plans 69 patients. At Emory University's Winship Cancer Institute in Atlanta, Conor Steuer leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.